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Abstract 14-3-3 proteins were the first signaling molecules to
be identified as discrete phosphoserine/threonine binding mod-
ules. This family of proteins, which includes seven isotypes in
human cells and up to 15 in plants, plays critical roles in cell
signaling events that control progress through the cell cycle,
transcriptional alterations in response to environmental cues, and
programmed cell death. Despite over 30 years of research,
distinct roles for most isotypes remain unknown. Though 14-3-3
proteins perform different functions for different ligands, general
mechanisms of 14-3-3 action include changes in activity of bound
ligands, altered association of bound ligands with other cellular
components, and changes in intracellular localization of 14-3-3-
bound cargo. We present a speculative model where binding of
14-3-3 to multiple sites on some ligands results in global ligand
conformational changes that mediate their biological effects. For
these multi-site ligands, one binding site is likely to function as a
‘gatekeeper’ whose phosphorylation is necessary for 14-3-3
binding but may not always be sufficient for full biological
activity. If correct, then 14-3-3 may prove to be a bona fide
phosphodependent signaling chaperone. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
14-3-3 proteins continue to generate intense interest because
of their roles in signal transduction pathways that control cell
cycle checkpoints, MAP kinase activation, apoptosis and pro-
grams of gene expression. Historically, 14-3-3 proteins were
identi¢ed as abundant polypeptides of unknown function in
brain [1], and later re-discovered as activators of tryptophan
and tyrosine hydroxylase [2,3] and inhibitors of PKCs [4].
Interest in 14-3-3 proteins grew when they were subsequently
identi¢ed as molecules that co-associated with Raf and poly-
oma middle T antigen [5^8], and as molecules implicated in
the DNA damage response of ¢ssion yeast [9]. Since then,
over 100 proteins have been found to interact with 14-3-3,
including various proteins kinases (PKCs, Raf family mem-
bers, KSR, PCTAIRE, MEKK1, -2 and -3, Bcr, PKUK,
ASK1), receptor proteins (glucocorticoid receptor, GpIb-IX,
K2 adrenergic receptor, GABA receptor, insulin-like growth
factor I receptor, IL-3/IL-5/GMCSF receptor Lc chain), en-
zymes (tyrosine and tryptophan hydroxylase, nitrate reduc-
tase, serotonin N-acetyl transferase, PTPH1 tyrosine phospha-
tase) structural and cytoskeletal proteins (vimentin, keratins
K8/K18, Tau, Kif1C), small G-proteins and their regulators
(Rem, Rad, RGS3/7, p190RhoGEF [10]), sca¡olding mole-
cules (IRS-1, calmodulin, Grb2, poloma middle T, p130Cas,
Cbl), proteins involved in cell cycle control (Cdc25 phospha-
tases, Chk1, Weel, p53, the catalytic subunit of human telo-
merase), proteins involved in transcriptional control of gene
expression (TATA box binding proteins TBP and TFIIB, his-
tone deacetylases 4,5, and 7, histone acetyl transferase 1, tran-
scription factors NFAT, Msn2p and 4p, and forkhead family
members, and the co-activators TAZ and YAP), and proteins
involved in control of apoptosis (BAD, A20 and the p75NTR-
associated cell death executor NADE) (See references [11^14]
for citations to primary literature and additional details). De-
spite this plethora of known binding proteins, in many cases
the function of 14-3-3 in these interactions has remained ob-
scure. In this review, I will brie£y summarize some of the
recent biochemical, structural, and genetic data that is helping
to elucidate the molecular basis of 14-3-3 function, and com-
ment on some of the outstanding questions that need to be
addressed. I present a model for how the 14-3-3 dimer might
function through simultaneously engaging multiple phosphor-
ylation sites on a single ligand, In this model, 14-3-3 stabilizes
non-native conformations of bound ligands to promote their
interactions with downstream targets, or facilitate their sub-
sequent modi¢cation by kinases and phosphatases.
2. 14-3-3 proteins: genetics, structure and mechanism
The term 14-3-3 denotes a large family of V30 kDa acidic
proteins that exist primarily as homo- and heterodimers with-
in all eukaryotic cells. Their unusual name refers to their
elution position on DEAE^cellulose chromatography and
gel electrophoresis during a systematic attempt at classifying
bovine brain proteins [1]. In humans, there are seven distinct
14-3-3 genes denoted L, Q, O, R, c, d (a) and j (as well as a
number of potential pseudogenes), while yeast and plants con-
tain between 2 and 15 genes [15,16]. Despite this genetic di-
versity, there is a surprisingly large amount of sequence iden-
tity and conservation [15,17,18] between all the 14-3-3 isotypes
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(Fig. 1). Stringently conserved regions either form the dimer
interface, or line the central ligand binding channel of the
dimeric 14-3-3 molecule [17], including many of residues
that form direct ligand contacts (Fig. 1).
Why then do we need so many isoforms? One possibility is
that di¡erent 14-3-3 molecules form distinct populations of
dimers with unique recognition motifs for ligands. Work by
Aitken and colleagues, however, demonstrated that several
di¡erent 14-3-3 isotypes are capable of forming mixed hetero-
dimers in vitro, and heterodimerization in vivo was demon-
strated for 14-3-3 O and j in co-transfection experiments [19].
In addition, the optimal phosphopeptide motif selected by
di¡erent 14-3-3 isotypes was extremely similar [20], and at
least some 14-3-3 ligands such as Raf-1 [17,21], Cas [22] and
Rem [23] appear to bind nearly equivalently to many, though
not all, 14-3-3 isotypes. A subset of ligands, however, clearly
bind to di¡erent 14-3-3 isotypes with signi¢cantly di¡erent
a⁄nities [24,25], and for most 14-3-3 binding ligands, a de-
tailed analysis of 14-3-3 isotype speci¢city in vitro or in vivo
has not been performed.
There are distinct spatial and temporal patterns of 14-3-3
gene expression during development in both plants (cf. [26])
and animals, particularly in the rodent brain and heart [27^
33], suggesting that there may be isotype-speci¢c developmen-
tal roles. Intriguingly, in Drosophila, which normally expresses
both 14-3-3 O and j (also called Leonardo), complete loss of
14-3-3 j, despite normal amounts of O, causes embryonic le-
thality [34], while single allelic mutations in j result in defects
in memory and learning [35,36]. In other aspects, such as Ras-
mediated MAP kinase activation, Drosophila 14-3-3 O and j
display at least partial redundancy [37].
Aside from development, isotype-speci¢c expression of 14-
3-3 proteins also appears to be a normal part of the cellular
response to injury. One particular isotype found primarily in
epithelial cells [38], 14-3-3 c, is strongly upregulated in colo-
rectal cancer cells following exposure to ionizing radiation
and DNA-damaging agents [39], and appears to be essential
for maintaining the G2/M checkpoint. The DNA damage-in-
duced upregulation of 14-3-3 c both in human colon carcino-
ma cells and in mouse ES cells occurs through a p53 and
BRCA1-mediated increase in gene transcription [39,40]. So-
matic cells lacking 14-3-3 c, initiate, but are unable to main-
tain a G2/M arrest following DNA damage and die by mitotic
catastrophe [41]. 14-3-3 c, in contrast to other 14-3-3 iso-
forms, does not bind to one of the major targets of 14-3-3
that mediates the G2/M checkpoint, namely the dual-speci¢c-
ity phosphatase Cdc25C [42]. Normal checkpoint signaling,
therefore, involves multiple isotype-speci¢c functions and sug-
gests that for c, another binding partner, perhaps cyclinB-
Cdc2 itself, is the G2/M checkpoint target [43]. A variety of
clinical observations further suggest that 14-3-3 c may func-
tion as a major tumor suppressor since it is frequently down-
regulated in breast and gastric cancer [44,45] as a result of
methylation of the 14-3-3 c promoter [46^48]. Curiously, 14-
3-3 c is upregulated in lung cancer [49], head and neck squa-
mous cell carcinomas [50], and chemoresistant pancreatic ad-
enocarcinoma cells [51]. Perhaps these increases re£ect a com-
pensatory response to alternative oncogenic mutations which
cause genomic instability and initiate a DNA damage check-
point in cells that still contain functional p53 alleles.
Increased levels of 14-3-3 Q have been observed in rat ca-
rotid arteries following balloon angioplasty injury [52,53], and
Fig. 1. Sequence alignment of human 14-3-3 isotypes. Residues conserved in at least six of the seven isotypes are shaded gray. The structure of
14-3-3 is indicated by helices above the alignment. Five conserved sequence blocks within the 14-3-3 family, as de¢ned by Wang and Shakes
[15], are indicated by a thin line below the alignment. Residues within the binding cleft that interact with peptide ligands or with the serotonin
N-acetyl transferase molecule are indicated by ¢lled circles. Acidic residues within the divergent C-termini are boxed.
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increased mRNA for j and d have been observed in rat moto-
neurons following axotomy [54]. Taken together, these ¢nd-
ings in cell injury, coupled with the developmental di¡erences
in 14-3-3 expression patterns, suggest that the balance be-
tween homo- and heterodimerization, as well as isotype re-
striction in heterodimer formation may be regulated in vivo.
Additional experimental data is clearly needed to further ad-
dress this issue.
How is 14-3-3 ligand binding controlled? The initial obser-
vation that 14-3-3 binding might require ligand phosphoryla-
tion emerged from work on tryptophan hydroxylase [55], an
enzyme involved in neurotransmitter biosynthesis, and Raf,
the upstream activator of the classical MAP kinase pathway
[56]. Pioneering investigation of the 14-3-3 binding sites on
Raf [57], together with oriented peptide library screening on
all mammalian 14-3-3s [20], led to the identi¢cation of two
optimal phosphoserine/threonine-containing motifs,
RSXpSXP and RXXXpSXP, that are recognized by all 14-
3-3 isotypes. In these consensus sequences pS denotes both
phosphoserine and phosphothreonine, and there is a moderate
to strong preference for particular amino acids over others in
the X positions [20]. Well over half of the 14-3-3 binding
proteins identi¢ed to date use phosphorylated sequences
which are reasonably close matches to the optimal 14-3-3
consensus motifs. The motifs are clearly not absolute, how-
ever, since the presence of a non-phosphorylated S immedi-
ately following R within the ¢rst motif, and a P two positions
C-terminal to the phosphorylated S or T in both motifs,
though strongly favored, is not required for peptide and pro-
tein binding to 14-3-3 [58]. Furthermore, there are several
examples of proteins and peptides containing dramatic varia-
tions from these motifs, including some that do not even
require phosphorylation for binding such as exoenzyme S
[59], A20 [24], the platelet glycoprotein IB^IX^V complex
[60,61] and a 14-3-3 binding peptide, R18, obtained by phage
display [62]. Atypical phosphorylated and non-phosphorylat-
ed sequences, including YpTV [63], KGQSTpSRG [64] and
GHSL [60,61], directly mediate 14-3-3 binding for these li-
gands, though most likely other parts of the proteins also
aid in the 14-3-3 interaction.
The X-ray structures of 14-3-3 d and j in the absence of
bound ligand showed that the molecule was a cup-shaped
dimer [65,66] (Fig. 2). Each monomer contains nine K-helices
(denoted KA^KI) with the dimer interface formed from helices
KA, KC and KD. Helices KE^KI form the side walls and roof
of a 35U35U20 Aî central channel that forms the binding
clefts for peptide and protein ligands. Maximal isotype diver-
gence occurs in an acidic-rich stretch at the extreme C-termi-
nus following helix KI (Fig. 1), a region of the protein which,
unfortunately, is not seen in any of the X-ray structures. The
structures of several ligand-bound 14-3-3 complexes have now
been solved, including 14-3-3 j bound to peptides representing
both of the phosphoserine consensus motifs [17,20], a peptide
corresponding to the Ser-259 binding site in Raf-1, and the
non-phosphorylated R18 peptide [67]. The peptides in all
cases occupy similar positions, nestled within an amphipathic
groove where the central channel meets the side walls
[17,20,67], and are held in a highly extended conformation
by multiple contacts between the main chain amides and
side chains of residues in helices KE, KG and KI. The phos-
phopeptide phosphate forms ionic and hydrogen bonds with
three absolutely conserved basic residues, Lys-49, Arg-56, and
Arg-127, along with Tyr-128 (Fig. 3) which forms a solitary
basic pocket on this otherwise negatively charged molecule,
explaining why for many ligands, phosphorylation is the crit-
ical switch that regulates their 14-3-3 binding. Recently, the
structure of 14-3-3 j bound to a bona ¢de protein ligand, the
serotonin N-acetyl transferase molecule in complex with a
bisubstrate analog, was solved [68]. In this structure, the 14-
3-3 binding portion of the enzyme displays a very similar
conformation to that seen in isolated phosphopeptide:14-3-3
complexes, but in addition, 14-3-3 appeared to stabilize the
conformation of an adjacent region in the enzyme, causing
enhanced substrate binding and product formation.
This structure, therefore, provides the ¢rst glimpse at
atomic resolution of one of the general mechanisms of 14-3-
3 action, namely the (1) direct regulation of catalytic activity
of the bound protein. The other equally important general
Fig. 2. The structure of 14-3-3 in two orthogonal views. Helices
KA^KI are shown as cylinders.
Fig. 3. A model for 14-3-3-dependent conformational change upon
multi-site binding. 14-3-3 binding relies initially upon interaction of
a gatekeeper residue with one monomeric subunit (1). Binding of
one or more weaker secondary sites (2) facilitates ligand conforma-
tions that is not favorable in the unbound state, exposing one or
more regions of the protein (shaded circle) that are inaccessible in
the free or monomer-bound form.
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mechanisms that underlie 14-3-3 function include (2) regulat-
ing interactions between the bound protein and other mole-
cules within the cell through sequestation or modi¢cation, and
(3) controlling the subcellular localization of bound ligands.
A major clue to understanding the mechanistic basis of 14-
3-3 function seems to be an appreciation of its dimeric nature,
with its two ligand binding clefts running in opposite direc-
tions. A ligand molecule containing multiple 14-3-3 binding
motifs might therefore be able to simultaneously engage both
monomeric subunits within a single dimer. Intriguingly, Raf
and FKHRL family members contain at least two 14-3-3
binding sites, as do the 14-3-3 binding proteins CBL [69],
BAD [69], and yeast forms of Cdc25C [70]. A synthetic phos-
phopeptide with two 14-3-3 consensus motifs binds over 30-
fold more tightly than the same peptide containing only a
single motif [20], and individual 14-3-3 binding sites located
at the N- and C-termini of serotonin N-acetyl transferase
allow a single molecule to interact simultaneously with both
subunits in a 14-3-3 dimer through this type of bidentate
interaction [68]. Furthermore, point mutations that disrupt
the 14-3-3 dimer signi¢cantly impair 14-3-3’s ability to coop-
erate in Raf signaling [71], as well as its ability to modulate
signaling by DAF-16, the Caenorhabditis elegans homologue
of the forkhead transcription factor FKHRL [72]. Thus, in
the model shown in Fig. 3, 14-3-3 regulates signaling events
through causing conformational changes in its bound ligands
by virtue of multiple interacting sites.
For most proteins, it seems likely that there is a single
dominant site that functions as a ‘gatekeeper’. If the site is
absent or not phosphorylated, then the secondary sites are too
weak to promote a stable 14-3-3 interaction. In contrast, once
the gatekeeper site is phosphorylated and bound to one
monomer in the 14-3-3 dimer, the secondary sites are able
to interact with the other monomeric subunit by virtue of
their high local concentration induced by its proximity. Map-
ping these secondary sites, if they exist, becomes quite chal-
lenging, since mutations are likely to have only a minor e¡ect
on total ligand:14-3-3 binding, which is what one usually
measures. The signi¢cance of potential secondary sites will
only be revealed when the 14-3-3 binding assay directly mea-
sures the e¡ects of binding on ligand function.
The 14-3-3 molecule appears to be extraordinarily rigid due
to a distributed series of interactions between the K-helices.
There is a negligible amount of movement between the free
and peptide-bound forms of 14-3-3 [17], and the average RMS
deviation among 426 CK carbons in the serotonin N-acetyl
transferase-bound form of 14-3-3 and the peptide-bound
form barely exceeds 1 Aî [68]. Thus, 14-3-3 behaves in essence
like a molecular anvil, deforming its bound ligands while itself
undergoing only minimal structural alterations. What func-
tion might these conformational changes in the ligand accom-
plish? In the case of serotonin N-acetyl transferase, and pre-
sumably exoenzyme S, 14-3-3 binding deforms the catalytic
residues so as to promote substrate binding and product for-
mation, perhaps through inducing a conformation that stabil-
izes the transition state of the enzyme:substrate complex. For
other proteins, 14-3-3-mediated conformational changes might
facilitate their interaction with other proteins, leading to en-
hanced post-translational modi¢cations such as phosphoryla-
tion, or alternatively, might facilitate subcellular relocalization
by deforming and/or masking a nuclear localization signal
(NLS) or nuclear export signal (NES) [73], or perhaps
through facilitating interactions between cryptic NES/NLS
sequences and nuclear importers or exporters.
There are a few examples where this type of tandem 14-3-3
binding has been clearly shown to be functionally important,
most prominently for Raf, although the exact role of 14-3-3 in
catalytic regulation of Raf continues to be controversial. All
Raf isoforms contain two 14-3-3 binding sites, one located in
the regulatory region and one located within the catalytic
portion of the molecule. For c-Raf-1, binding of 14-3-3 to
the regulatory region appears to suppress the basal catalytic
activity, but maintains the inactive form near the plasma
membrane in a form that is readily re-activatable [74] when
the N-terminal segment is displaced from 14-3-3 through de-
phosphorylation and binding to Ras [75,76]. In addition,
binding of the C-terminal part of c-Raf-1 is required for main-
tenance of catalytic activity [77]. Thus, only 14-3-3 dimers,
which can interact simultaneously with both the N- and C-
terminal portions of Raf, in contrast to monomeric 14-3-3
subunits, are capable of facilitating Raf activation [71]. If
14-3-3 binding to the N- and C-termini did not induce a gen-
eral conformational change, and instead had only local e¡ects
on the isolated catalytic and regulatory domains, then it is
di⁄cult to understand why monomeric 14-3-3 would not func-
tion equally well. The role of 14-3-3 proteins in regulation of
A-Raf and B-Raf is less well understood, but as with c-Raf-1,
14-3-3 proteins may play an additional role in regulating their
interaction with other upstream or downstream e¡ector mol-
ecules [78^82].
It seems certain that there will be a number of 14-3-3 li-
gands where this type of tandem binding does not occur or is
irrelevant to their function. In those cases, 14-3-3 might func-
tion as a molecular adaptor, coupling independent 14-3-3
binding molecules in a single complex as has been proposed
for complexes between BCR and Raf [83], PKCj and Raf [79],
and A20 and Raf [24]. Obviously, the model shown in Fig. 3
remains speculative, and de¢nitive proof will require the crys-
tal structure of additional 14-3-3-ligands, both free and in
complex with 14-3-3.
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